Pod Insights a16z Podcast Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde About this episode Traditional drug development is like single-use rockets—costly and bespoke. But, inspired by SpaceX's rocket reusability, imagine programmable medicines that reuse components, transforming the way we innovate.
General PartnerJorge Conde shares his Big Idea for 2024 and how the FDA is embracing this shift, adopting the FAA's approach to aviation safety for transparent and flexible evaluations of programmable medicines.
Timecodes:
00:00 - Big Ideas in Tech 2024
01:39 - Programming Medicine’s Final Frontier
03:07 - The three stages of developing drugs in 2023
06:35 - The impact of programmable medicine
10:48 - The FDA and office of The Office of Therapeutic Products
16:01 - What does programmable medicine unlock for business?
17:52 - Regulation, cost, and access
Resources:
View all 40+ big ideas: https://a16z.com/bigideas2024
Find Jorge on Twitter: https://twitter.com/JorgeCondeBio
Stay Updated:
Find a16z on Twitter: https://twitter.com/a16z
Find a16z on LinkedIn: https://www.linkedin.com/company/a16z
Subscribe on your favorite podcast app: https://a16z.simplecast.com/
Follow our host: https://twitter.com/stephsmithio
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosure
Transcript 0:00 Speaker 1 Precision delivery of medicine. Entertainment franchise games absolutely exploding. Small moduli reactors and the nuclear renaissance, plus AI moving into very complex workflows. Now these were just a few of the major tech innovations that partners at A16Z predicted last year. And our partners are back. And we just dropped our list of over 40 plus big ideas for 2024. A compilation of critical advancements across all our verticals, from smart energy grids to crime detecting computer vision to democratizing miracle drugs like GLP1s, or even AI moving from black box to clearbox. You can find the full list of 40 plus builder-worthy pursuits at A16Z.com/slash big ideas 2024.
0:45 Speaker 1 Or you can click the link in our description below. But on deck today, you will hear directly from one of our partners as we dive even more deeply into their big idea. What's the why now? What opportunities and what challenges are on the horizon? And how can you get involved? Let's dive in. As a reminder, the content here is for informational purposes only, should not be taken as legal, business, tax or investment advice, or be used to evaluate any investment or security, and is not directed at any investors or potential investors in any A16Z fund. Please note that A16Z and its affiliates may also maintain investments in the companies discussed in this podcast. For more details, including a link to our investments, please see A16C.com/slash disclosures.
1:39 Speaker 0 Hi, my name is Jorge Conde. I'm one of the general partners here at Adriason Horowitz. I'm on the BioN Health team where I focus on investments in the life sciences. My big idea for the year is programming medicine's final frontier. Where are the reusable rockets for biotech? Traditional drug development is painstakingly time consuming, risky, and expensive. It's highly bespoke too. One molecule has no bearing on the next molecule that gets developed. Like traditional rockets, they're one-time use only. That's changing. SpaceX's rocket reusability has transformed space travel, lowering costs and expanding horizons. Similarly, potentially curative programmable medicines like gene therapy can reuse components like the develop delivery vehicles used to target specific cells while swapping out the genetic cargo.
2:29 Speaker 0 The next mission uses the same rocket to deliver a different payload to a new destination. The FDA is looking to the skies and taking a page out of the FAA's approach to aviation safety, rigorous yet adaptive. Recently launching its own new office for therapeutic products and pilot piloting operation warp speed for rare disease to create more transparent and flexible processes for evaluating and approving programmable medicines. Imagine a future where we redeploy, not reinvent innovation. It will revolutionize how we make medicines and where these medicines can take us.
3:05 Speaker 1 All right. So Jorge, I feel like this big idea is so compelling. This idea of programming medicine certainly sounds like something that uh the whole world could benefit from. But before we get into that, maybe you could just break down a little bit further why traditional drug development is, as you say, so painstakingly time consuming, risky, and expensive. And maybe also just put a number to that. Like how long does it really take for drugs to be developed in 2023 terms?
3:35 Speaker 0 Sure. So first of all, the reason why it's so painstaking, it's so time consuming, it's risky and expensive, is because we're putting something into human beings. And so, of course, the bar of what we're going to do should be and is exceedingly high. Uh, in terms of how long it takes, um, you know, there these are averages of averages, of course, but on average, it could take anywhere between 10 to 15 years to develop a drug uh to get it to patients. And that's obviously a very, very long time, especially in diseases where people are desperately in need for better treatments.
4:10 Speaker 1 So, why does it take 10 to 15 years typically?
4:14 Speaker 0 Well, typically there are three stages in in developing a medicine, right? The first one is what we would call, you know, the actual drug discovery stage, which is you know, the work that goes into, you know, finding a target in a disease that you would like to hit with a medicine.
4:31 Speaker 1 Um,
4:31 Speaker 0 in some cases, that target is already known. In some cases, uh, you're looking to discover new targets to go after to have better treatment options for a given disease.
4:41 Speaker 1 That
4:41 Speaker 0 can take many, many years, even in that first phase. The second phase is what we call preclinical development. So now it's this work of once you have a target you think is worth hitting, and you have a molecule that you think hits that target, you have to do all of the work to develop that molecule into a medicine to ensuring that it has all the qualities of what you want a medicine to have in terms of how it's absorbed and how it's metabolized and where it goes to in the body and whether or not it's toxic, and if so, you know, how much of it is toxic. All of that work we do in in what we call preclinical development outside of humans. We do this in in in dishes and cells. We can do this in animal models like mice or even monkeys. Uh, and that, as you can imagine, also takes many, many years.
5:28 Speaker 0 And then, of course, there's the third phase, which is the most important phase, which is what we call clinical development, uh, which is the you know uh the terms that uh many would be familiar with uh in terms of human clinical trials, where there's a phase one trial, a phase two trial, and a phase three trial. And that process can take anywhere between five to seven years. And so when you add up all of those phases, the drug discovery phase, the preclinical development phase, the clinical development phase, that's how you get to these 10 to 15 years. And I should add that once you're done with clinical trials, you now have to file for regulatory approval. So here in the US, you file with the FDA. The process by which these applications get reviewed reviewed by the FDA, you know, despite the FDA's best efforts, can take one, sometimes even two years to go through.
6:19 Speaker 0 So again, when you sum all of that up, it's um it's you can see why it can often take well over a decade to make a medicine.
6:26 Speaker 1 Absolutely. And to your point, the bar being high is a very reasonable concept. But where does programmable medicine come into play here and how does that maybe change the paradigm across each of those stages, or where does it have the potential to really reshape that arc?
6:43 Speaker 0 Yeah, so I think this is where um the concept of a programmable medicine potentially could be um very transformative to how we think about developing drugs. Uh, and that is uh because in the programmable medicine, there are multiple components that could be uh, as I as I described, redeployed for different applications. So let me give you an example. Um, a gene therapy is this idea that you can deliver uh uh a genetic payload, in other words, you can deliver a gene to a cell that has a defective version of that gene. If we're able to make a medicine that does that, that can deliver one gene to a given cell type, it becomes increasingly likely that we'll be able to deliver a different gene to a different cell type for a different disease.
7:32 Speaker 0 And that's very different than the way we traditionally make medicines. If you think about a traditional medicine, like a chemical, a molecule, that is a chemical that is tested and designed for uh a specific disease at a specific target. The second you switch the target, we don't reuse the atoms in the molecule and try to fit them into a new target. We just design a different molecule. And that's why I say, you know, in traditional drug development, one molecule has very little bearing on the next molecule you design. But in the case of these programmable medicines, where all the components can be reused, uh, you just have to essentially redirect or redeploy um uh components like you know, delivery vehicles for gene therapies, or in the case of a gene editing medicine, just redirect what edit you want the um the enzyme or the protein to make.
8:27 Speaker 0 And that is where the programmability comes in.
8:32 Speaker 1 And that sounds huge, right? Just so I understand you correctly, when you're talking about the reuse the reusability of um these medicines, it's basically the equivalent of the reusable rocket is the um almost like the um you basically would have already gotten a certain drug approved to be able to deliver something each time you're reiterating on that. Would you then need to have the the specific genetic um almost like payload in there reapproved, but most of that legw has already been done. Am I thinking about that correctly?
9:09 Speaker 0 That's right. In this analogy, what we what we would love to see uh become possible is that you know, the rocket in that in this case is the vehicle by which you ensure that your payload is delivered, right? And some of the most common ones that we know in terms of what would be rockets here are uh the LNP uh molecules that all of the COVID vaccines that many of us received were delivered in. Right. The COVID vaccine was mRNA. MRNA had the instruction for what it wanted your body to make, and that was encapsulated in this LNP uh particle, lipid nanoparticle. It's like a little ball of fat. Similarly, for a lot of gene therapies, instead of using an LMP particle, we use something called an AAV, which is an adapted virus.
9:57 Speaker 0 It stands for Dino Associated Virus. There have been examples in the clinic where payloads have been delivered with LNP or payloads have been delivered with AAV. For different applications, all you're swapping out is the cargo, the instruction in the of mRNA that's in that LMP or the instructions or the or the genetic cargo that's in that AAB. And this is very timely because the FDA is starting to signal that they are looking for ways to be increasingly adaptive to ensure that we can they can adequately review these therapies that are reusing components, but do so in a way that will be both rigorous but also adaptive and therefore hopefully more speedy.
10:42 Speaker 1 And where people don't have to start from scratch because they already have that rocket that is reapplicable. So tell us a little more about that, where the FDA seems to be taking maybe some inspiration, or at least that's what you allude to with the FAA, right? So what can we what can they learn from the rocket reusability in this analogy? And what also may be fundamentally different. And what are you taking from some of the new announcements like the new office of therapeutic products?
11:09 Speaker 0 Yeah, so I think there's a lot of things to take from this. The first one is that I think there is there's there's real recognition here that we are seeing meaningful in innovation uh in terms of the kinds of medicines we can make. And the FDA is appropriately uh trying to find ways to remain uh to retain their rigor, because again, they have an extraordinarily high obligation to ensure safety and efficacy in patients, but to um move um hopefully more quickly to attempt to keep up with all the innovation we're seeing. And so they've uh uh pushed forward on several fronts that I think are already uh pointing us in that direction. The first one is they've announced an office of therapeutic products whose uh mandate and mission is to find ways to do uh exactly what we've been describing.
12:02 Speaker 0 And so I think uh I think the industry, the drug development industry now has a partner in the FDA in trying to find the best path forward
12:12 Speaker 1 along the
12:12 Speaker 0 lines of what we talked about. The second is they they are also uh trying to innovate themselves. The FDA is looking to be more nimble and is running experiments to uh find ways to do uh exactly that. So for example, um we all are many of us would be familiar with operation warp speed, which was the effort by the government to try to ensure that the COVID vaccines could reach all of us in a very, very timely manner, given the nature of the pandemic. Well, the FDA has said there are so many intractable diseases, many rare genetic diseases that have no good therapeutic or treatment options. So they are launching a pilot program mirroring the concept of operation warp speed, uh, but to apply that to rare diseases where they are going to run some experiments to see different ways that the agency can interact with industry uh to get these medicines uh more quickly to the patients that so desperately need them.
13:10 Speaker 0 And so I think those are very, very um promising signs that um both the industry and and the government are looking for ways to ensure ensure these innovations reach patients in a in a timely and responsible manner. And there's also other proof points that we can point to that are happening um uh every day, right now. So for example, um several companies that are developing cutting-edge gene editing uh uh medicines are starting to get approvals by the FDA to move forward with some of their key uh clinical trials. And there'd been a moment in time where the FDA was being more hesitant, but I think as they've as they've started to evaluate these technologies more carefully, they've started to uh develop uh path forward for these uh medicines to continue to get developed.
13:59 Speaker 0 And the breaking news is that the first CRISPR therapy has been approved. Uh this is a therapy for sickle cell anemia and um beta thalassemia that was developed by a biotech biopharmaceutical company called Vertex Pharmaceuticals, uh, working with another company called CRISPR Therapeutics. Um, and this is a therapy for essentially curing uh a genetic disease, in this case, sickle cell anemia, by taking the cells, the relevant cells out of the body, editing them uh with uh with the the CRISPR uh gene editing uh technology and putting them back in the body uh in a way that results in a functional cure. And this is a big deal for so many reasons. The first one is it's the first time that a CRISPR therapy has been approved as a medicine.
14:46 Speaker 1 Yeah. Um
14:47 Speaker 0 the second reason why this is a big idea, uh a big deal is that I think it's an important milestone on this uh to this point about the future of what programmable medicines could look like. Now that you have a first approval, could you you've demonstrated that a CRISPR uh editor could be safely used as a medicine. So now if it adds it something differently, the process for getting that approved should hopefully be you know shorter and faster. And the third reason I think that this is a big uh deal in terms of a milestone is how relatively speaking, how quickly this has happened. So you asked me at the beginning, how long does it take uh make to how long does it take to make a drug? And I said about 10 to 15 years on average. It's barely been 10 years since the concept of CRISPR was discovered and described in the scientific literature.
15:37 Speaker 1 Right. So
15:38 Speaker 0 we went from the initial discovery of CRISPR as a potential uh use uh as a medicine all the way to an approval in just over 10 years. That is lightning fast uh in this world. So it's just an exciting moment in time, I think for for the industry and hopefully for for all the various patients that are looking for better solutions uh and treatments for their diseases.
16:01 Speaker 1 Maybe you could just speak a little more to that, like if we are able to see this confluence that you're discussing and this idea of programmable medicine becoming a reality, what does that really mean in in terms of like the the speed of therapies um coming, the number of them, the new business models that might be unlocked, how this might ultimately end uh end up impacting patients, any just kind of high-level thoughts about this if we are moving to this new paradigm, what that really means?
16:30 Speaker 0 Yeah, I think it means a couple of things. Uh the first one uh is I think it means that um for the benefit of patients, every time we run a clinical trial with these types of medicines, we're not starting from from square zero or from square one, because we already know something about the various components in the therapy. So that's the first thing. The second thing is that generally speaking, these programmable medicines are going after diseases where the cause of the disease is very well known. In other words, it's a known mutation, and it's the ability to intervene has been uh in an effective way has been what's been elusive for us. So, and in a lot of ways, these new programmable medicines are just a fundamentally new superpower.
17:16 Speaker 0 We can go after diseases that we weren't able to go after before. And as a result, the third thing that I think this means for all of us is that we may be on the cusp where you know the elusive C word is a reality, that we might actually have cures for lots of very intractable problems. And that is a very new day indeed, right? Like that is something that it just has not been very common in in our industry. So I think there's lots of reasons to be excited.
17:44 Speaker 1 Yeah, I mean, I as you're talking, I'm like actually smiling because it's it is there is it's hard, it's impossible not to be excited. But I guess just to close things off, you've painted this beautiful picture of what may be to come. Could you share a little bit more about the blockers, if any, whether regulatory, whether it has to do with the fundamental science that's coming on board? What would you say if this reality that you're painting uh were to not come to pass? What would those reasons be? And also maybe for those listening, how can builders get involved? How can they actually help make this reality come true?
18:21 Speaker 0 Yeah. So, first of all, in terms of the blockers, uh, I think there are several, um, and I think they are important. Um, and some of the blockers should be there. Um, so the first one is uh everything I'm describing in terms of these programmable medicines has another side of it has another side of the coin to it, which is these are largely speaking permanent medicines as well. So, you know, if you if you take a pill and you have a bad uh you know a reaction or adverse event or toxic reaction to that pill, you just stop taking the pill. And eventually your body will clear it and you know, hopefully um, you know, the toxicity has been addressed. In the case of making a permanent edit in DNA, if there is an error, if there is a toxicity that comes from making that edit, something inadvertent, it's permanent, or at least it has the potential to be permanent.
19:14 Speaker 0 And so for that reason, the FDA appropriately has extraordinarily high bar for how they think about um evaluating the safety of these medicines, and um how they think about which diseases are probably the most appropriate to go after with something that is potentially a cure, but also potentially permanent.
19:34 Speaker 1 Yeah. So
19:34 Speaker 0 that's one blocker that you know is just going to need it's going to need to be addressed systematically. And it should be. A second blocker is, you know, one of the most the only medicines that work are the ones that get to patients. And these programmable medicines have a couple of challenges in terms of accessibility. The first one is um these are not pills. You get over the counter. These are very complex medicines. And so therefore the process by which you get treated can be a very long and difficult process. So I just described the approval of CRISPR therapy for sickle cell anemia.
20:20 Speaker 1 Yep.
20:20 Speaker 0 The process by which you get the treatment could take months because you have to go, you have to get your cells removed, the cells get edited. In this case, you actually have to get a form of therapy to kill your internal cells so you can replace it with the corrected ones afterwards. And that hope, and that could be a long stay at the hospital. So that whole process could take several months. So the accessibility of these therapies will limit how many people can get them and when. And the second element to accessibility is cost. And today, uh, these therapies can cost on the order of millions of dollars. Now, on the one hand, that millions of dollars of cost is justified because a lot of RD went into it.
21:06 Speaker 0 They're very extensive, expensive to make and manufacture. It's very expensive to manufacture all these components I'm describing. And that's number two. And then number three, they provide a fair amount of benefit. You know, in the case of treating a baby that had something like somatic muscular atrophy that would have otherwise died, a one and done gene therapy uh from Navardis, this is uh uh therapy that's worth about its cost about 2.1 million dollars, effectively um uh saves that baby's life. So there's an incredible amount of value that comes from that.
21:43 Speaker 1 Absolutely.
21:44 Speaker 0 But the cost of discovering, developing, manufacturing these therapies and the benefit that they come from also comes with a very hefty price tag, and that's going to limit accessibility. So that's one of the other key blockers I would say that we're seeing in this in this space. Now, how can builders help? I think builders can help in a very important way, which is if there is one technology on this planet that can scale better than anything else we know of, it's biology. And so all of the things I'm describing in terms of blockers to access at some point can be addressed by improving our ability to engineer biology to address some of these limitations. So improved biology can make manufacturing much more scalable and therefore um much less expensive.
22:33 Speaker 0 Uh, improving the kinds of uh of interventions and the precision by which these programmable medicines work can address some of these questions of permanence or toxicity. So, where the builders can really help is just become better programmers versus biology, and from that, we will get better applications at higher scale and at lower cost, and hopefully get them in the hands of patients more quickly.
22:59 Speaker 1 That's amazing. And maybe one super quick question to end things off is you know, a lot of our listeners are familiar with the idea of exponential uh exponentially decreasing cost in things like software. Um do you see that same uh kind of curve being applied here when you're talking about decreasing costs? Is that really the future that you're painting where these things instead of costing millions of dollars, we're talking thousands? Is that really in the future?
23:24 Speaker 0 That's the hope. Um, and the possibility is there because again, you know, uh biology can scale exponentially. We all did come from one cell, and here we are, we're sitting here.
23:34 Speaker 1 That's such a great point.
23:36 Speaker 0 Yeah, so I think um, you know, but there's work to be done there. We haven't seen it yet. Absolutely. But that's the promise, and that's the hope.
23:42 Speaker 1 All right, I hope you enjoyed this big idea. We do have a lot more on the way, including a new age of maritime exploration that takes advantage of AI and computer vision, plus AI first games that never end, and whether Voice first apps may finally be having their moment. By the way, if you want to see our full list of 40 plus big ideas today, you can head on over to A6CZ.com/slash big ideas 2024. It's time to build
24:30 UNKNOWN a
Previous Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo Next 2024 Big Ideas: AI-First Games That Never End with Jonathan Lai Page updated August 25, 2026 · transcript and summary are machine-generated